22,285 Shares in Insulet Corporation $PODD Purchased by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Insulet Corporation (NASDAQ:PODD) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 22,285 shares of the medical instruments supplier’s stock, valued at approximately $7,002,000.

Other hedge funds have also added to or reduced their stakes in the company. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in shares of Insulet by 7.7% during the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 134,357 shares of the medical instruments supplier’s stock valued at $42,212,000 after acquiring an additional 9,578 shares during the period. Aviva PLC grew its holdings in Insulet by 6.7% during the second quarter. Aviva PLC now owns 52,189 shares of the medical instruments supplier’s stock valued at $16,397,000 after purchasing an additional 3,282 shares during the period. Los Angeles Capital Management LLC increased its position in Insulet by 518.0% in the second quarter. Los Angeles Capital Management LLC now owns 167,231 shares of the medical instruments supplier’s stock worth $52,541,000 after buying an additional 140,169 shares during the last quarter. Metis Global Partners LLC raised its stake in shares of Insulet by 6.4% in the second quarter. Metis Global Partners LLC now owns 3,842 shares of the medical instruments supplier’s stock valued at $1,207,000 after buying an additional 230 shares during the period. Finally, Penserra Capital Management LLC purchased a new position in shares of Insulet during the 2nd quarter valued at $67,000.

Insider Buying and Selling

In other Insulet news, SVP Prem Singh sold 687 shares of Insulet stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the sale, the senior vice president directly owned 3,456 shares in the company, valued at $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Laetitia Cousin sold 797 shares of the stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the transaction, the senior vice president directly owned 3,890 shares in the company, valued at $1,356,870.90. The trade was a 17.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 0.39% of the company’s stock.

Insulet Price Performance

NASDAQ:PODD opened at $336.84 on Thursday. Insulet Corporation has a 52-week low of $230.05 and a 52-week high of $353.50. The stock has a fifty day moving average of $324.17 and a 200 day moving average of $311.37. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. The firm has a market capitalization of $23.70 billion, a price-to-earnings ratio of 102.38, a P/E/G ratio of 2.64 and a beta of 1.39.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating the consensus estimate of $1.13 by $0.11. The firm had revenue of $521.70 million for the quarter, compared to analysts’ expectations of $678.70 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The company’s revenue was up 29.9% compared to the same quarter last year. During the same quarter last year, the firm posted $1.08 EPS. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, research analysts expect that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Analysts Set New Price Targets

PODD has been the subject of several recent research reports. Raymond James Financial lifted their price objective on Insulet from $360.00 to $366.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. Wall Street Zen upgraded shares of Insulet from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Canaccord Genuity Group boosted their price target on shares of Insulet from $399.00 to $428.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Rothschild & Co Redburn raised their price objective on shares of Insulet from $350.00 to $370.00 and gave the stock a “buy” rating in a report on Friday, October 3rd. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Insulet from $340.00 to $415.00 and gave the company an “overweight” rating in a research note on Friday, September 12th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, Insulet currently has a consensus rating of “Moderate Buy” and a consensus target price of $374.10.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.